Ethics of Offshoring: Novo Nordisk and Clinical Trials in Emerging Economies Harvard Case Solution & Analysis

The case summarizes the conflicting ethical demands on a Danish pharmaceuticals business, Novo Nordisk, that's operating globally and is aspiring to high standards of corporate social responsibility. A recent report alleges that multinational pharmaceutical companies routinely run trials in developing countries under alleged unethical conditions. The manager of the company's reflects on just how to react to a request from a journalist for an interview. This triggers a discussion on the ethical principles that are proper and the best way to convey them.

As a business highlighting corporate responsibility, the interaction with the media presents both opportunities and hazards to Novo Nordisk. The case focuses on clinical trials that are required to achieve regulatory acceptance in, for example, North America and Europe, and that are conducted at multiple sites all over the world, including many emerging markets.

PUBLICATION DATE: January 09, 2009 PRODUCT #: 909M01-HCB-ENG

This is just an excerpt. This case is about ORGANIZATIONAL DEVELOPMENT

Share This